MedElevator Войти в исследования
← Поиск публикаций

DOI 10.36401/jipo-22-14

Медицинская библиотека · Journal of immunotherapy and precision oncology · 2022

Highlights on Ocular Toxicity of Immune Checkpoint Inhibitors at a US Tertiary Cancer Center.

Mazharuddin Anam A, Whyte Andrew T, Gombos Dan S, Patel Nimisha, Razmandi Azadeh, Chaudhry Amina L, Al-Zubidi Nagham S

СтатьяПеревод в очереди

Аннотация

INTRODUCTION

Immune checkpoint inhibitors (ICIs) have improved prognosis in advanced malignancies; however, they may be associated with extensive ocular immune-related adverse events (irAEs) that are sight threatening. Our study aimed to identify the presentation, characteristics, management, and clinical outcomes of ocular irAEs.

METHODS

In this retrospective, observational case series, we reviewed the medical records of 1280 patients at a large US tertiary cancer center between 2010 and 2020.

RESULTS

We identified 130 patients who presented with ocular irAEs (10%) with 69 males (53%) and 61 females (47%). The mean time to toxicity was 6.1 months. Adverse events include corneal toxicity (31%), neuro-ophthalmic (14%), uveitis and scleritis (13%), retinopathy (13%), periocular disorders (11%), and others. IrAEs occurred most frequently with nivolumab (26%). Most ocular irAEs were treated with topical therapy. Advanced cases required systemic corticosteroids and even cessation of ICIs.

CONCLUSION

Our cohort is a large case series highlighting the increased potential of ocular toxicity associated with ICIs. Prompt recognition and management of ocular irAEs can minimize their effect.

Для цитирования: Mazharuddin Anam A, Whyte Andrew T, Gombos Dan S, Patel Nimisha, Razmandi Azadeh, Chaudhry Amina L, Al-Zubidi Nagham S. Highlights on Ocular Toxicity of Immune Checkpoint Inhibitors at a US Tertiary Cancer Center.. Journal of immunotherapy and precision oncology. 2022. DOI: 10.36401/jipo-22-14.
Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.